<p>Gilman Hill Asset Management LLC 在第三季度减少了对 Organon &amp; Co.（纽约证券交易所代码：OGN - 免费报告）股票的持有，减持幅度达到 87.3%，根据其最近向证券交易委员会的披露。该公司在季度内出售了 177,746 股后，持有 25,935 股 Organon &amp; Co. 的股票。Gilman Hill Asset Management LLC 在 Organon &amp; Co. 的持股在最近的报告期末价值为 277,000 美元。</p>
<ul>
<li>默克，道琼斯最热门的股票，准备公布第四季度财报</li>
</ul>
<p>其他一些机构投资者也增加或减少了对 OGN 的持股。True North Advisors LLC 在第三季度购买了价值约 158,000 美元的 Organon &amp; Co. 新头寸。Douglas Lane &amp; Associates LLC 在第三季度将其在 Organon &amp; Co. 的持股增加了 40.5%。Douglas Lane &amp; Associates LLC 现在拥有 443,876 股该公司的股票，价值 4,741,000 美元，此前在上个季度又购买了 127,924 股。GAMMA Investing LLC 在第三季度将其在 Organon &amp; Co. 的持股增加了 22.4%。GAMMA Investing LLC 现在拥有 6,910 股该公司的股票，价值 74,000 美元，此前在上个季度又收购了 1,265 股。Osaic Holdings Inc. 在第二季度将其在 Organon &amp; Co. 的持股增加了 25.5%。Osaic Holdings Inc. 现在拥有 60,791 股该公司的股票，价值 594,000 美元，此前在上个季度又收购了 12,363 股。最后，Orion Porfolio Solutions LLC 在第二季度将其在 Organon &amp; Co. 的持股增加了 96.5%。Orion Porfolio Solutions LLC 现在拥有 63,509 股该公司的股票，价值 615,000 美元，此前在上个季度又收购了 31,190 股。对冲基金和其他机构投资者持有该公司 77.43% 的股票。</p>
<p>获取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>一些券商最近对 OGN 进行了评估。摩根大通将 Organon &amp; Co. 的目标价从 14.00 美元下调至 12.00 美元，并在 11 月 11 日的报告中对该股票给予了 “减持” 评级。巴克莱在 12 月 9 日的报告中开始覆盖 Organon &amp; Co. 的股票。他们对该股票给予了 “减持” 评级，并设定了 7.50 美元的目标价。派珀·桑德勒在 10 月 27 日的研究报告中将 Organon &amp; Co. 的股票评级从 “增持” 下调至 “减持”，并设定了 5.00 美元的目标价。摩根士丹利在 11 月 11 日的报告中将 Organon &amp; Co. 的目标价从 10.00 美元下调至 9.00 美元，并对该股票给予了 “持平” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 Organon &amp; Co. 股票的 “卖出（d+）” 评级。一位分析师对该股票给予了强烈买入评级，两位给予了持有评级，四位给予了卖出评级。根据 MarketBeat，该公司的平均评级为 “减持”，共识目标价为 8.38 美元。</p>
<ul>
<li>Lululemon Athletica 股价因进入 S&amp;P 500 而飙升至新高</li>
</ul>
<p><strong>获取我们关于 Organon &amp; Co. 的最新研究报告</strong></p>
<h2>Organon &amp; Co. 股价上涨 0.1%</h2>
<p>OGN 周四开盘价为 7.10 美元。该公司的市值为 18.4 亿美元，市盈率为 3.70，PEG 比率为 1.52，贝塔值为 0.57。Organon &amp; Co. 的一年低点为 6.18 美元，一年高点为 17.23 美元。该公司的 50 日简单移动平均为 7.44 美元，200 日简单移动平均为 9.03 美元。该公司的债务与股本比率为 9.69，流动比率为 1.75，速动比率为 1.20。</p>
<p>Organon &amp; Co.（纽约证券交易所代码：OGN - 获取免费报告）最近一次公布财报是在 11 月 10 日，报告显示该公司季度每股收益为 1.01 美元，超出分析师共识预期的 0.93 美元，超出幅度为 0.08 美元。Organon &amp; Co. 的股本回报率为 143.47%，净利润率为 7.95%。该公司在本季度的收入为 16 亿美元，而共识预期为 15.7 亿美元。在去年同期，该公司的每股收益为 1.38 美元。分析师预测 Organon &amp; Co. 在当前年度的每股收益将达到 3.68 美元。</p>
<h2>Organon &amp; Co. 股息公告</h2>
<p>该公司最近还宣布了季度股息，于 12 月 11 日支付。11 月 20 日的股东记录将获得每股 0.02 美元的股息。除息日期为 11 月 20 日。这相当于每年 0.08 美元的股息，股息收益率为 1.1%。Organon &amp; Co. 的股息支付比率为 4.17%。</p>
<h2>关于 Organon &amp; Co.</h2>
<p>（免费报告）</p>
<p>Organon &amp; Co. 是一家全球医疗保健公司，于 2021 年 6 月从默克公司分拆后成立为独立的上市实体。公司总部位于新泽西州泽西市，Organon 专注于提供女性健康、生物类似药和成熟品牌的治疗解决方案。公司的创建反映了专注于具有显著患者影响的专业药品和传统产品的战略努力。</p>
<p>在女性健康领域，Organon 提供广泛的产品组合，解决生殖和妇科疾病，包括生育治疗、避孕和激素替代疗法。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Organon &amp; Co.</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
<p><strong>想看看其他对 OGN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Organon &amp; Co.（纽约证券交易所代码：OGN - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Organon &amp; Co.吗？</h2>
<p>在考虑 Organon &amp; Co.之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Organon &amp; Co.并不在名单上。</p>
<p>虽然 Organon &amp; Co.目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Gilman Hill Asset Management LLC 在第三季度减少了对 Organon & Co. 的持股，减幅达到 87.3%，目前持有 25,935 股，价值 277,000 美元。其他投资者也调整了他们的持股，分析师对 OGN 的评级各不相同。该股票开盘价为 7.10 美元，市值为 18.4 亿美元。Organon 报告第三季度每股收益为 1.01 美元，超出预期，并宣布派发 0.02 美元的股息</p>

<p>Gilman Hill Asset Management LLC lessened its holdings in shares of Organon &amp; Co. (NYSE:OGN - Free Report) by 87.3% in the third quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 25,935 shares of the company's stock after selling 177,746 shares during the quarter. Gilman Hill Asset Management LLC's holdings in Organon &amp; Co. were worth $277,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Gilman Hill Asset Management LLC 在第三季度减少了对 Organon &amp; Co.（纽约证券交易所代码：OGN - 免费报告）股票的持有，减持幅度达到 87.3%，根据其最近向证券交易委员会的披露。该公司在季度内出售了 177,746 股后，持有 25,935 股 Organon &amp; Co. 的股票。Gilman Hill Asset Management LLC 在 Organon &amp; Co. 的持股在最近的报告期末价值为 277,000 美元。</p>
</div><ul>
<li>Merck, the Dow's hottest stock, gets set to report Q4 financials</li>
</ul>
<div class="lb-trans"><ul>
<li>默克，道琼斯最热门的股票，准备公布第四季度财报</li>
</ul>
</div><p>A number of other institutional investors have also added to or reduced their stakes in OGN. True North Advisors LLC purchased a new position in Organon &amp; Co. during the 3rd quarter valued at about $158,000. Douglas Lane &amp; Associates LLC grew its position in Organon &amp; Co. by 40.5% during the third quarter. Douglas Lane &amp; Associates LLC now owns 443,876 shares of the company's stock worth $4,741,000 after buying an additional 127,924 shares in the last quarter. GAMMA Investing LLC increased its stake in Organon &amp; Co. by 22.4% in the 3rd quarter. GAMMA Investing LLC now owns 6,910 shares of the company's stock worth $74,000 after acquiring an additional 1,265 shares during the last quarter. Osaic Holdings Inc. increased its stake in Organon &amp; Co. by 25.5% in the 2nd quarter. Osaic Holdings Inc. now owns 60,791 shares of the company's stock worth $594,000 after acquiring an additional 12,363 shares during the last quarter. Finally, Orion Porfolio Solutions LLC raised its holdings in shares of Organon &amp; Co. by 96.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 63,509 shares of the company's stock valued at $615,000 after acquiring an additional 31,190 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者也增加或减少了对 OGN 的持股。True North Advisors LLC 在第三季度购买了价值约 158,000 美元的 Organon &amp; Co. 新头寸。Douglas Lane &amp; Associates LLC 在第三季度将其在 Organon &amp; Co. 的持股增加了 40.5%。Douglas Lane &amp; Associates LLC 现在拥有 443,876 股该公司的股票，价值 4,741,000 美元，此前在上个季度又购买了 127,924 股。GAMMA Investing LLC 在第三季度将其在 Organon &amp; Co. 的持股增加了 22.4%。GAMMA Investing LLC 现在拥有 6,910 股该公司的股票，价值 74,000 美元，此前在上个季度又收购了 1,265 股。Osaic Holdings Inc. 在第二季度将其在 Organon &amp; Co. 的持股增加了 25.5%。Osaic Holdings Inc. 现在拥有 60,791 股该公司的股票，价值 594,000 美元，此前在上个季度又收购了 12,363 股。最后，Orion Porfolio Solutions LLC 在第二季度将其在 Organon &amp; Co. 的持股增加了 96.5%。Orion Porfolio Solutions LLC 现在拥有 63,509 股该公司的股票，价值 615,000 美元，此前在上个季度又收购了 31,190 股。对冲基金和其他机构投资者持有该公司 77.43% 的股票。</p>
</div><p>Get <strong>Organon &amp; Co.</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Organon &amp; Co.</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of brokerages recently weighed in on OGN. JPMorgan Chase &amp; Co. decreased their price objective on Organon &amp; Co. from $14.00 to $12.00 and set an &#34;underweight&#34; rating on the stock in a report on Tuesday, November 11th. Barclays assumed coverage on shares of Organon &amp; Co. in a report on Tuesday, December 9th. They set an &#34;underweight&#34; rating and a $7.50 target price on the stock. Piper Sandler lowered shares of Organon &amp; Co. from an &#34;overweight&#34; rating to an &#34;underweight&#34; rating and set a $5.00 price target for the company. in a research report on Monday, October 27th. Morgan Stanley decreased their price objective on Organon &amp; Co. from $10.00 to $9.00 and set an &#34;equal weight&#34; rating on the stock in a report on Tuesday, November 11th. Finally, Weiss Ratings restated a &#34;sell (d+)&#34; rating on shares of Organon &amp; Co. in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and four have issued a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of &#34;Reduce&#34; and a consensus target price of $8.38.</p>
<div class="lb-trans"><p>一些券商最近对 OGN 进行了评估。摩根大通将 Organon &amp; Co. 的目标价从 14.00 美元下调至 12.00 美元，并在 11 月 11 日的报告中对该股票给予了 “减持” 评级。巴克莱在 12 月 9 日的报告中开始覆盖 Organon &amp; Co. 的股票。他们对该股票给予了 “减持” 评级，并设定了 7.50 美元的目标价。派珀·桑德勒在 10 月 27 日的研究报告中将 Organon &amp; Co. 的股票评级从 “增持” 下调至 “减持”，并设定了 5.00 美元的目标价。摩根士丹利在 11 月 11 日的报告中将 Organon &amp; Co. 的目标价从 10.00 美元下调至 9.00 美元，并对该股票给予了 “持平” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重申了对 Organon &amp; Co. 股票的 “卖出（d+）” 评级。一位分析师对该股票给予了强烈买入评级，两位给予了持有评级，四位给予了卖出评级。根据 MarketBeat，该公司的平均评级为 “减持”，共识目标价为 8.38 美元。</p>
</div><ul>
<li>Lululemon Athletica Races to New High with S&amp;P 500 Entry</li>
</ul>
<div class="lb-trans"><ul>
<li>Lululemon Athletica 股价因进入 S&amp;P 500 而飙升至新高</li>
</ul>
</div><p><strong>Get Our Latest Research Report on Organon &amp; Co.</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Organon &amp; Co. 的最新研究报告</strong></p>
</div><h2>Organon &amp; Co. Trading Up 0.1%</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 股价上涨 0.1%</h2>
</div><p>OGN opened at $7.10 on Thursday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 3.70, a PEG ratio of 1.52 and a beta of 0.57. Organon &amp; Co. has a one year low of $6.18 and a one year high of $17.23. The business has a 50 day simple moving average of $7.44 and a two-hundred day simple moving average of $9.03. The company has a debt-to-equity ratio of 9.69, a current ratio of 1.75 and a quick ratio of 1.20.</p>
<div class="lb-trans"><p>OGN 周四开盘价为 7.10 美元。该公司的市值为 18.4 亿美元，市盈率为 3.70，PEG 比率为 1.52，贝塔值为 0.57。Organon &amp; Co. 的一年低点为 6.18 美元，一年高点为 17.23 美元。该公司的 50 日简单移动平均为 7.44 美元，200 日简单移动平均为 9.03 美元。该公司的债务与股本比率为 9.69，流动比率为 1.75，速动比率为 1.20。</p>
</div><p>Organon &amp; Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.08. Organon &amp; Co. had a return on equity of 143.47% and a net margin of 7.95%.The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the prior year, the company earned $1.38 earnings per share. Analysts predict that Organon &amp; Co. will post 3.68 EPS for the current year.</p>
<div class="lb-trans"><p>Organon &amp; Co.（纽约证券交易所代码：OGN - 获取免费报告）最近一次公布财报是在 11 月 10 日，报告显示该公司季度每股收益为 1.01 美元，超出分析师共识预期的 0.93 美元，超出幅度为 0.08 美元。Organon &amp; Co. 的股本回报率为 143.47%，净利润率为 7.95%。该公司在本季度的收入为 16 亿美元，而共识预期为 15.7 亿美元。在去年同期，该公司的每股收益为 1.38 美元。分析师预测 Organon &amp; Co. 在当前年度的每股收益将达到 3.68 美元。</p>
</div><h2>Organon &amp; Co. Dividend Announcement</h2>
<div class="lb-trans"><h2>Organon &amp; Co. 股息公告</h2>
</div><p>The company also recently announced a quarterly dividend, which was paid on Thursday, December 11th. Shareholders of record on Thursday, November 20th were issued a dividend of $0.02 per share. The ex-dividend date was Thursday, November 20th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 1.1%. Organon &amp; Co.'s dividend payout ratio is 4.17%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度股息，于 12 月 11 日支付。11 月 20 日的股东记录将获得每股 0.02 美元的股息。除息日期为 11 月 20 日。这相当于每年 0.08 美元的股息，股息收益率为 1.1%。Organon &amp; Co. 的股息支付比率为 4.17%。</p>
</div><h2>About Organon &amp; Co.</h2>
<div class="lb-trans"><h2>关于 Organon &amp; Co.</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Organon &amp; Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck &amp; Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.</p>
<div class="lb-trans"><p>Organon &amp; Co. 是一家全球医疗保健公司，于 2021 年 6 月从默克公司分拆后成立为独立的上市实体。公司总部位于新泽西州泽西市，Organon 专注于提供女性健康、生物类似药和成熟品牌的治疗解决方案。公司的创建反映了专注于具有显著患者影响的专业药品和传统产品的战略努力。</p>
</div><p>In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.</p>
<div class="lb-trans"><p>在女性健康领域，Organon 提供广泛的产品组合，解决生殖和妇科疾病，包括生育治疗、避孕和激素替代疗法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Organon &amp; Co.</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Organon &amp; Co.</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元 AI 奇迹股票” 即将爆发</li>
<li>任何费用可以从资本利得税中扣除吗？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>忘掉 AI，这将是下一个重大科技突破</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding OGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon &amp; Co. (NYSE:OGN - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 OGN 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Organon &amp; Co.（纽约证券交易所代码：OGN - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU9HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=OGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Organon &amp; Co. Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Organon &amp; Co.吗？</h2>
</div><p>Before you consider Organon &amp; Co., you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Organon &amp; Co.之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon &amp; Co. wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Organon &amp; Co.并不在名单上。</p>
</div><p>While Organon &amp; Co. currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Organon &amp; Co.目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Gilman Hill Asset Management LLC 减少了其在 Organon & Co. $OGN 的持仓